Bcl-2 expression predicts sensitivity to chemotherapy in breast cancer: A systematic review and meta-analysis

Journal of Experimental and Clinical Cancer Research

Volumn 32, Issue 1, 2013, Pages

  Yang, Dong ^a   Chen, Min Bin ^a   Wang, Li Qiang ^a   Yang, Lan ^b   Liu, Chao Ying ^c   Lu, Pei Hua ^c  

^a JIANGSU UNIVERSITY   (China)

^b THE THIRD AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Bcl 2; Breast cancer; Chemotherapy; Response

Indexed keywords

ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOADJUVANT THERAPY; PROTO-ONCOGENE PROTEINS C-BCL-2; TAXOIDS; TREATMENT OUTCOME;

EID: 84890992190     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-32-105     Document Type: Review

References (39)

1. A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with breast cancer. Sekine I, Shimizu C, Nishio K, Saijo N, Tamura T, Int J Clin Oncol 2009 14 2 112 119 10.1007/s10147-008-0813-z 19390941
2. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Ni Chonghaile T, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore Vdel G, Deng J, Anderson KC, Richardson P, Tai YT, et al. Science 2011 334 6059 1129 1133 10.1126/science.1206727 22033517
3. Control of mitochondrial apoptosis by the Bcl-2 family. Brunelle JK, Letai A, J Cell Sci 2009 122 Pt 4 437 441 19193868
4. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Oltvai ZN, Milliman CL, Korsmeyer SJ, Cell 1993 74 4 609 619 10.1016/0092-8674(93)90509-O 8358790 (Pubitemid 23259742)
5. Molecular profile of the BCL2 family of the apoptosis related genes in breast cancer cells after treatment with cytotoxic/cytostatic drugs. Thomadaki H, Scorilas A, Connect Tissue Res 2008 49 3 261 264 18661356
6. Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance. Davis JM, Navolanic PM, Weinstein-Oppenheimer CR, Steelman LS, Hu W, Konopleva M, Blagosklonny MV, McCubrey JA, Clin Cancer Res 2003 9 3 1161 1170 12631622 (Pubitemid 36323726)
7. Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Vo TT, Ryan J, Carrasco R, Neuberg D, Rossi DJ, Stone RM, Deangelo DJ, Frattini MG, Letai A, Cell 2012 151 2 344 355 10.1016/j.cell.2012.08.038 23063124
8. ABT-737 reverses the acquired radioresistance of breast cancer cells by targeting Bcl-2 and Bcl-xL. Li JY, Li YY, Jin W, Yang Q, Shao ZM, Tian XS, J Exp Clin Cancer Res 2012 31 102 10.1186/1756-9966-31-102 23259599
9. Reporting results of cancer treatment. Miller AB, Hoogstraten B, Staquet M, Winkler A, Cancer 1981 47 1 207 214 10.1002/1097-0142(19810101)47:1<207:: AID-CNCR2820470134>3.0.CO;2-6 7459811 (Pubitemid 11167383)
10. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, et al. J Natl Cancer Inst 2000 92 3 205 216 10.1093/jnci/92.3.205 10655437
11. Measuring inconsistency in meta-analyses. Higgins JP, Thompson SG, Deeks JJ, Altman DG, BMJ 2003 327 7414 557 560 10.1136/bmj.327.7414.557 12958120 (Pubitemid 37088507)
12. Low expression of NQO1 predicts pathological complete response to neoadjuvant chemotherapy in breast cancer patients treated with TAC regimen. Grim J, Jandik P, Slanska I, Dolezalova-Brcakova E, Fuksa L, Ryska A, Knizek J, Petera J, Micuda S, Hornychova H, Folia Biol (Praha) 2012 58 5 185 192 23249637
13. Measuring beta-tubulin III, Bcl-2, and ERCC1 improves pathological complete remission predictive accuracy in breast cancer. Chen X, Wu J, Lu H, Huang O, Shen K, Cancer Sci 2012 103 2 262 268 10.1111/j.1349-7006.2011.02135.x 22035021
14. Survivin as a predictive biomarker of complete pathologic response to neoadjuvant chemotherapy in patients with stage II and stage III breast cancer. Petrarca CR, Brunetto AT, Duval V, Brondani A, Carvalho GP, Garicochea B, Clin Breast Cancer 2011 11 2 129 134 10.1016/j.clbc.2011.03.002 21569999
15. Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast. von Minckwitz G, Sinn HP, Raab G, Loibl S, Blohmer JU, Eidtmann H, Hilfrich J, Merkle E, Jackisch C, Costa SD, et al. Breast Cancer Res 2008 10 2 30 10.1186/bcr1989 18380893
16. Prognostic value of Bcl-2 in breast cancer patients treated with neoadjuvant anthracycline based chemotherapy. Vargas-Roig LM, Cuello-Carrion FD, Fernandez-Escobar N, Daguerre P, Leuzzi M, Ibarra J, Gago FE, Nadin SB, Ciocca DR, Mol Oncol 2008 2 1 102 111 10.1016/j.molonc.2008.01.004 19383332
17. Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. Keam B, Im SA, Kim HJ, Oh DY, Kim JH, Lee SH, Chie EK, Han W, Kim DW, Moon WK, et al. BMC Cancer 2007 7 203 10.1186/1471-2407-7-203 17976237 (Pubitemid 351193977)
18. Apoptosis induced by neoadjuvant chemotherapy in breast cancer. Tiezzi DG, De Andrade JM, Reis FJ C d, Marana HR, Ribeiro-Silva A, Tiezzi MG, Pereira AP, Pathology 2006 38 1 21 27 10.1080/00313020500465315 16484003 (Pubitemid 43259247)
19. Predictive factors for response to docetaxel in human breast cancers. Noguchi S, Cancer Sci 2006 97 9 813 820 10.1111/j.1349-7006.2006.00265.x 16805818 (Pubitemid 44151259)
20. Tumour response to preoperative anthracycline-based chemotherapy in operable breast cancer: the predictive role of p53 expression. Mieog JS, Van Der Hage JA, Van De Vijuer MJ, Van De Velde CJ, Cooperating Investigators of the E, Eur J Cancer 2006 42 10 1369 1379 10.1016/j.ejca.2006.01.054 16766179 (Pubitemid 44183848)
21. Clinical and pathological predictors of the response to neoadjuvant anthracycline chemotherapy in locally advanced breast cancer. Fernandez-Sanchez M, Gamboa-Dominguez A, Uribe N, Garcia-Ulloa AC, Flores-Estrada D, Candelaria M, Arrieta O, Med Oncol 2006 23 2 171 183 10.1385/MO:23:2:171 16720917 (Pubitemid 43780300)
22. Predictive biological markers for response of invasive breast cancer to anthracycline/cyclophosphamide-based primary (radio-)chemotherapy. Prisack HB, Karreman C, Modlich O, Audretsch W, Danae M, Rezai M, Bojar H, Anticancer Res 2005 25 6C 4615 4621 16334152 (Pubitemid 41729522)
23. High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer. Kim SJ, Miyoshi Y, Taguchi T, Tamaki Y, Nakamura H, Yodoi J, Kato K, Noguchi S, Clin Cancer Res 2005 11 23 8425 8430 10.1158/1078-0432.CCR-05-0449 16322305 (Pubitemid 41746957)
24. The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer. Buchholz TA, Garg AK, Chakravarti N, Aggarwal BB, Esteva FJ, Kuerer HM, Singletary SE, Hortobagyi GN, Pusztai L, Cristofanilli M, et al. Clin Cancer Res 2005 11 23 8398 8402 10.1158/1078-0432.CCR-05-0885 16322301 (Pubitemid 41746953)
25. Expression of BAG-1 and BcL-2 proteins before and after neoadjuvant chemotherapy of locally advanced breast cancer. Pusztai L, Krishnamurti S, Perez Cardona J, Sneige N, Esteva FJ, Volchenok M, Breitenfelder P, Kau SW, Takayama S, Krajewski S, et al. Cancer Invest 2004 22 2 248 256 10.1081/CNV-120030213 15199607 (Pubitemid 38725179)
26. Can patients' likelihood of benefiting from primary chemotherapy for breast cancer be predicted before commencement of treatment? Ogston KN, Miller ID, Schofield AC, Spyrantis A, Pavlidou E, Sarkar TK, Hutcheon AW, Payne S, Heys SD, Breast Cancer Res Treat 2004 86 2 181 189 10.1023/B:BREA.0000032986.00879. d7 15319570 (Pubitemid 38988021)
27. The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile. Mathieu MC, Rouzier R, Llombart-Cussac A, Sideris L, Koscielny S, Travagli JP, Contesso G, Delaloge S, Spielmann M, Eur J Cancer 2004 40 3 342 351 10.1016/j.ejca.2003. 08.015 14746851 (Pubitemid 38121270)
28. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer. Stearns V, Singh B, Tsangaris T, Crawford JG, Novielli A, Ellis MJ, Isaacs C, Pennanen M, Tibery C, Farhad A, et al. Clin Cancer Res 2003 9 1 124 133 12538460 (Pubitemid 36109724)
29. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Geisler S, Lonning PE, Aas T, Johnsen H, Fluge O, Haugen DF, Lillehaug JR, Akslen LA, Borresen-Dale AL, Cancer Res 2001 61 6 2505 2512 11289122 (Pubitemid 32685830)
30. Clinicopathologic Analysis of Fas, Fas Ligand, and Other Biomarkers in Locally Advanced Breast Carcinoma. Pernick NL, Biernat L, Du W, Visscher DW, Breast J 2000 6 4 233 241 10.1046/j.1524-4741.2000.98087.x 11348371 (Pubitemid 30622095)
31. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. Bottini A, Berruti A, Bersiga A, Brizzi MP, Brunelli A, Gorzegno G, DiMarco B, Aguggini S, Bolsi G, Cirillo F, et al. Clin Cancer Res 2000 6 7 2751 2758 10914720 (Pubitemid 30482114)
32. Primary chemotherapy in operable breast cancer with favorable prognostic factors: a pilot study evaluating the efficacy of a regimen with a low subjective toxic burden containing vinorelbine, 5-fluorouracil and folinic acid (FLN). Nole F, Minchella I, Colleoni M, Orvieto E, Munzone E, de Braud F, Peruzzotti G, Martinelli G, Zampino MG, Catania C, et al. Ann Oncol 1999 10 8 993 996 10.1023/A:1008389106575 10509165 (Pubitemid 29424583)
33. Prediction of response to primary chemotherapy for operable breast cancer. Colleoni M, Orvieto E, Nole F, Orlando L, Minchella I, Viale G, Peruzzotti G, Robertson C, Noberasco C, Galimberti V, et al. Eur J Cancer 1999 35 4 574 579 10.1016/S0959-8049(99)00005-2 10492630 (Pubitemid 29192965)
34. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Makris A, Powles TJ, Dowsett M, Osborne CK, Trott PA, Fernando IN, Ashley SE, Ormerod MG, Titley JC, Gregory RK, et al. Clin Cancer Res 1997 3 4 593 600 9815725 (Pubitemid 27211838)
35. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL, Carney DA, He SZ, Huang DC, Xiong H, et al. J Clin Oncol 2012 30 5 488 496 10.1200/JCO.2011.34.7898 22184378
36. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Wilson WH, O'Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP, Tulpule A, Dunleavy K, Xiong H, Chiu YL, et al. Lancet Oncol 2010 11 12 1149 1159 10.1016/S1470-2045(10)70261-8 21094089
37. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, Johnson EF, Marsh KC, Mitten MJ, Nimmer P, et al. Cancer Res 2008 68 9 3421 3428 10.1158/0008-5472. CAN-07-5836 18451170
38. Assessment of predictive markers of response to neoadjuvant chemotherapy in breast cancer. Tewari M, Pradhan S, Singh U, Singh TB, Shukla HS, Asian J Surg 2010 33 4 157 167 10.1016/S1015-9584(11)60001-8 21377101
39. P53 status as a predictive biomarker for patients receiving neoadjuvant radiation-based treatment: a meta-analysis in rectal cancer. Chen MB, Wu XY, Yu R, Li C, Wang LQ, Shen W, Lu PH, PLoS One 2012 7 9 45388 10.1371/journal.pone. 0045388 23049793